Vivus’ commercial launch of Qsymia this week
beat its weight loss rival, Arena Pharmaceuticals’ drug Belviq. In addition,
Qsymia’s release conveniently precedes the Obesity Society annual meeting in
San Antonio. While doctors will be discussing both drugs at the meeting, only
Vivus will have its weight loss pill on the market and ready for prescriptions
when doctors return home to their patients.
The release date does not
seem to be a coincidence. Qsymia hit pharmacy shelves most likely as a result
of careful timing on Vivus’ part. As the new weight loss drug is gaining
attention, its commercial availability during the Obesity Society meeting will
only boost interest.
Unfortunately, the push
for such a speedy release may have been a hasty decision. There are still many
lingering concerns regarding the known side effects of topiramate and
phentermine, the two active drugs in Qsymia.
0 comments:
Post a Comment